Metformin for diabetes with heart disease
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial tests a long-acting metformin pill in people with both type 2 diabetes and coronary heart disease. It aims to see if metformin can safely help control blood sugar in this specific group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 75 years old
- You have type 2 diabetes with an A1C between 7% and 9%, and fasting blood sugar between 7 and 10 mmol/L
- You either are newly diagnosed and only using diet and exercise, or you've been on DPP-4 inhibitors or SGLT2 inhibitors for at least 12 weeks
- You have coronary heart disease confirmed by angiogram and are on standard heart medications including aspirin and metoprolol
- You have not used GLP-1 drugs (like Ozempic) or metformin in the last 4 weeks
- You do not have severe heart failure, kidney failure, liver problems, pancreatitis, or cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three diabetes medicines (henagliflozin proline, retagliptin, and metformin) for people newly diagnosed with type 2 diabetes. The goal is to see how well the combination controls blood sugar and to check its safety.
This study compares different diabetes medicines to see which works best for people with type 2 diabetes who also have heart or blood vessel risks. It aims to find better treatment to protect your heart and kidneys.
This study tests a new medicine (HM11260C) to see if it helps people with type 2 diabetes who are already taking metformin and dapagliflozin but still have high blood sugar. If you qualify, it could give you a new option to better control your diabetes.
This study tests a new pill called HDM1002 for adults with type 2 diabetes. It aims to see if it helps control blood sugar when added to your current metformin treatment.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
This trial tests if newer diabetes medications can reduce heart risk and help achieve diabetes remission in people newly diagnosed with type 2 diabetes. It may be an option if you have not taken diabetes drugs before or stopped them over three months ago, and your blood sugar and weight are in certain ranges.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.